IMTX Stock Summary and Trading Ideas (Immatics N.V. - | NASDAQ:IMTX)

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Immatics N.V. - trades on the NASDAQ stock market under the symbol IMTX.

As of November 9, 2026, IMTX stock price climbed to $6.43 with 629,150 million shares trading.

IMTX has a beta of 1.82, meaning it tends to be more sensitive to market movements. IMTX has a correlation of 0.25 to the broad based SPY ETF.

IMTX has a market cap of $978.81 million. This is considered a Small Cap stock.

Last quarter Immatics N.V. - reported $11 million in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.10.

In the last 3 years, IMTX traded as high as $13.77 and as low as $3.30.

The top ETF exchange traded funds that IMTX belongs to (by Net Assets): SPDW, SBIO, KOMP, CANC, ONEQ.

IMTX has underperformed the market in the last year with a price return of -30.3% while the SPY ETF gained +13.4%. IMTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.7% and -12.0%, respectively, while the SPY returned -1.8% and -1.0%, respectively.

IMTX support price is $6.08 and resistance is $6.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMTX shares will trade within this expected range on the day.